NDA 021060 · Esteve
Prialt
Ziconotide Acetate · Intrathecal
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 28, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 2 recruiting
FAERS reports
2,435
1,162 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms. WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS See full prescribing information for complete boxed warning Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Do not treat patients with a pre-existing history of psychosis with PRIALT
What it is approved for
From the label in effect Sep 15, 2026.
PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. ( 1 )
Mechanism: Ziconotide binds to N-type calcium channels located on the primary nociceptive (A-δ and C) afferent nerves in the superficial layers (Rexed laminae I and II) of the dorsal horn in the spinal cord. Although the mechanism of action of ziconotide has not been established in humans, results in animals suggest that its binding blocks N-type calcium channels, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals and antinociception.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 28, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
4 products under this application
- PRIALT · ZICONOTIDE ACETATE 500MCG/20ML (25MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
- PRIALT · ZICONOTIDE ACETATE 500MCG/5ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
- PRIALT · ZICONOTIDE ACETATE 100MCG/1ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
- PRIALT · ZICONOTIDE ACETATE 200MCG/2ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ziconotide" as an intervention, any sponsor and status, largest first.
- Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe PainPivotal-lookingCompleted
Elan PharmaceuticalsIndustry
NCT00076544 · 300 participants · Start Feb 2004 · Primary completion Mar 2005
Drug: Ziconotide · For: Pain
Sites: Huntsville, Alabama; Sun City West, Arizona; Tucson, Arizona · 65 sites in all
- Prialt (Ziconotide) In Severe Chronic PainPivotal-lookingCompleted
Elan PharmaceuticalsIndustry
NCT00047749 · 220 participants · Start Aug 2002
Drug: Prialt (ziconotide) · For: Pain
Sites: Huntsville, Alabama; Northport, Alabama; Tucson, Arizona · 44 sites in all
NeurexIndustry
NCT00002160 · 100 participants
Drug: Ziconotide · For: HIV Infections; Cancer; Pain
Sites: Huntsville, Alabama; Mobile, Alabama; Northport, Alabama · 44 sites in all
- Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory NeuropathicPivotal-lookingStatus unknown
Hospices Civils de LyonAcademic, hospital or other
NCT03942848 · 44 participants (planned) · Start Jun 20, 2019 · Primary completion Dec 20, 2019
Drug: zicotinide followed by placebo; Placebo followed by zicotinide · For: Severe Refractory Neuropathic Pain; Spinal Cord Lesions
- Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic CancerNot yet recruiting
Clinique BizetAcademic, hospital or other
NCT07733427 · 40 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Drug: Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections · For: Pancreatic Cancer Pain; Intrathecal Analgesic; Intrathecal Administration of the Drug and 1 more
Sites: Paris, France · 3 sites in all
University Hospital, LinkoepingAcademic, hospital or other
NCT01373983 · 26 participants · Start Aug 2011 · Primary completion Dec 2014
Drug: Ziconotide · For: Peripheral Neuropathy
Sites: Linköping, Sweden
- Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With CancerStatus unknown
National Cancer Institute, NaplesAcademic, hospital or other
NCT00996983 · 16 participants (planned) · Start Sep 2009 · Primary completion Dec 2024
Drug: ziconotide · For: Pain; Neuropathic Pain; Intractable Pain and 1 more
Sites: Naples, Italy
- Ziconotide as First-Line IDTCompleted
Albany Medical CollegeAcademic, hospital or other
NCT03321955 · 13 participants · Start Nov 3, 2016 · Primary completion Aug 30, 2020
Drug: Ziconotide 100 MCG(microgram)/ML Intrathecal Solution · For: Neuropathic Pain
Sites: Albany, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain362
- device issue313
- off label use302
- drug ineffective241
- confusional state205
- nausea205
- hallucination168
- dizziness157
- headache136
- hallucination, auditory133
- memory impairment104
- fall101
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 75 |
| 2006 | 97 |
| 2007 | 102 |
| 2008 | 28 |
| 2009 | 30 |
| 2010 | 37 |
| 2011 | 50 |
| 2012 | 66 |
| 2013 | 61 |
| 2014 | 96 |
| 2015 | 118 |
| 2016 | 392 |
| 2017 | 304 |
| 2018 | 268 |
| 2019 | 211 |
| 2020 | 26 |
| 2021 | 125 |
| 2022 | 82 |
| 2023 | 83 |
| 2024 | 70 |
| 2025 | 74 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prialt (Ziconotide Acetate)
2024 spending
$58K
Beneficiaries
n/a
15 claims
Per beneficiary
n/a
$747.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $85,297 |
| 2021 | $81,902 |
| 2022 | $107,552 |
| 2023 | $99,046 |
| 2024 | $57,579 |
Part B: Prialt (Ziconotide Acetate) · HCPCS J2278
2024 spending
$3.6M
Beneficiaries
322
1,120 claims
Per beneficiary
$11,278
2024 ASP limit $9.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,916,504 |
| 2021 | $4,488,250 |
| 2022 | $4,158,857 |
| 2023 | $3,671,203 |
| 2024 | $3,631,398 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intrathecal ziconotide for refractory pain.
Doggrell SA · Expert Opin Investig Drugs 2004 · Clinical Trial, Controlled Clinical Trial
- Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.
Brookes ME, Eldabe S, Batterham A · Curr Neuropharmacol 2017 · Systematic Review
- Intrathecal Baclofen Monotherapy and Polyanalgesia for Treating Chronic Pain in Patients with Severe Spasticity.
Marathe A, Allahabadi S, Abd-Elsayed A, et al. · Curr Pain Headache Rep 2021 · Systematic Review
- Long-term intrathecal ziconotide for chronic pain: an open-label study.
Webster LR, Fisher R, Charapata S, et al. · J Pain Symptom Manage 2009 · Clinical Trial, Multicenter Study
- Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine--the Raffaeli Detoxification Model.
Raffaeli W, Righetti D, Sarti D, et al. · J Opioid Manag 2011 · Clinical Trial, Research Support, Non-U.S. Gov't
- A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
Rauck RL, Wallace MS, Leong MS, et al. · J Pain Symptom Manage 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Esteve
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.